Press Release & Community Statement: Lexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxia

In a press release today, June 17, 2026, Lexeo Therapeutics announced that key results from Phase I/II studies of LX2006 gene therapy in Friedreich ataxia (FA) have been published in the Journal of the American Medical Association (JAMA) Cardiology.